These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30642922)

  • 1.
    Noviello S; Magnet S; Hawser S; Huang DB
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30642922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections.
    Huang DB; Corey GR; Holland TL; Lodise T; O'Riordan W; Wilcox MH; File TM; Dryden M; Balser B; Desplats E; Torres A
    Int J Antimicrob Agents; 2018 Aug; 52(2):233-240. PubMed ID: 29783024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The incidence and patient outcomes of ABSSSI by iclaprim MIC values in the phase 3 REVIVE trials for treatment of acute bacterial skin and skin structure infections.
    Huang DB; Charrier C; Le Bras C; Hawser S; Noviello S
    J Med Microbiol; 2019 Jun; 68(6):898-902. PubMed ID: 31050628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe.
    Huang DB; Magnet S; De Angelis S; Holland TL; File TM; Dryden M; Corey GR; Torres A; Wilcox MH
    Diagn Microbiol Infect Dis; 2019 Feb; 93(2):154-158. PubMed ID: 30266399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Surveillance of iclaprim activity: In vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and Europe.
    Huang DB; File TM; Dryden M; Corey GR; Torres A; Wilcox MH
    Diagn Microbiol Infect Dis; 2018 Apr; 90(4):329-334. PubMed ID: 29306582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potency and bactericidal activity of iclaprim against recent clinical gram-positive isolates.
    Sader HS; Fritsche TR; Jones RN
    Antimicrob Agents Chemother; 2009 May; 53(5):2171-5. PubMed ID: 19289528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Worldwide surveillance of Iclaprim activity: In Vitro susceptibility of gram-positive pathogens collected from patients with skin and skin structure infections from 2013 to 2017.
    Huang DB; Charrier C; Hawser S
    Diagn Microbiol Infect Dis; 2020 May; 97(1):115013. PubMed ID: 32081524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1.
    Huang DB; O'Riordan W; Overcash JS; Heller B; Amin F; File TM; Wilcox MH; Torres A; Dryden M; Holland TL; McLeroth P; Shukla R; Corey GR
    Clin Infect Dis; 2018 Apr; 66(8):1222-1229. PubMed ID: 29281036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
    Sader HS; Flamm RK; Jones RN
    Diagn Microbiol Infect Dis; 2013 May; 76(1):61-8. PubMed ID: 23535208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014.
    Pfaller MA; Mendes RE; Castanheira M; Flamm RK; Jones RN; Sader HS
    Pediatr Infect Dis J; 2017 May; 36(5):486-491. PubMed ID: 28403050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of dihydrofolate reductase inhibitors and other antibiotics against Gram-positive pathogens collected globally between 2004 and 2016.
    Noviello S; Hawser S; Sader H; Huang DB
    J Glob Antimicrob Resist; 2019 Mar; 16():236-238. PubMed ID: 30612987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
    Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
    J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vitro Activities of Tedizolid and Linezolid against Gram-Positive Cocci Associated with Acute Bacterial Skin and Skin Structure Infections and Pneumonia.
    Chen KH; Huang YT; Liao CH; Sheng WH; Hsueh PR
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6262-5. PubMed ID: 26248355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies.
    Krause KM; Barriere SL; Kitt MM; Benton BM
    Diagn Microbiol Infect Dis; 2010 Oct; 68(2):181-5. PubMed ID: 20846593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity.
    Oefner C; Bandera M; Haldimann A; Laue H; Schulz H; Mukhija S; Parisi S; Weiss L; Lociuro S; Dale GE
    J Antimicrob Chemother; 2009 Apr; 63(4):687-98. PubMed ID: 19211577
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    McCurdy S; Lawrence L; Quintas M; Woosley L; Flamm R; Tseng C; Cammarata S
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections.
    Noviello S; Corey GR; Holland TL; Lodise T; O'Riordan W; Wilcox MH; File TM; Dryden M; Balser B; Scaramucci A; Torres A; Huang DB
    J Med Microbiol; 2020 Apr; 69(4):625-630. PubMed ID: 32195649
    [No Abstract]   [Full Text] [Related]  

  • 18. Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections.
    Krievins D; Brandt R; Hawser S; Hadvary P; Islam K
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2834-40. PubMed ID: 19414572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iclaprim: a differentiated option for the treatment of skin and skin structure infections.
    Noviello S; Huang DB; Corey GR
    Expert Rev Anti Infect Ther; 2018 Nov; 16(11):793-803. PubMed ID: 30317894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011).
    Pfaller MA; Flamm RK; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2014 Apr; 78(4):422-8. PubMed ID: 24445158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.